Analysts & Consensus

Dechra Pharmaceuticals PLC is followed by the analysts listed below.

Please note that any opinions, estimates or forecasts regarding Dechra Pharmaceuticals PLC’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Dechra Pharmaceuticals PLC or its management.

Dechra Pharmaceuticals PLC does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.




Sam England

BNP Paribas

Laurent Gelebert


Anand Date


Andrew Whiteney


James Vane-Tempest

JP Morgan

James Gordon


Edward Thomason


Kane Slutzkin

Panmure Gordan

Mike Mitchell

RBC Capital Markets

Zoe Karamanoli


Max Herrmann

The company-compiled consensus estimate for FY23 full-year underlying EBIT is £191 million with a range of £186 million to £199 million.  

Underlying results exclude items associated with amortisation and impairment of acquired intangibles and notional intangibles in respect of Medical Ethics, acquisition and integration costs including release of acquisition tax provisions, transformational cloud computing arrangements, loss on extinguishment of debt, foreign exchange and discount unwind relating to contingent consideration, the tax impact of these items and the deferred tax impact of changes in tax rates.

The consensus estimate is a simple arithmetical average of forecasts as at 28 November 2022 that have been published within the past six months by registered investment analysts and provided to Investor Relations at Dechra Pharmaceuticals PLC.  We reserve the right, from time to time, with or without notice, to exclude one or more analysts’ forecasts on the basis that we believe them to be unrepresentative and/or out of date.